Shares of Amyris Inc (NASDAQ:AMRS) have received an average recommendation of “Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.50.
AMRS has been the subject of a number of analyst reports. BidaskClub downgraded shares of Amyris from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Amyris in a research note on Tuesday, August 7th. Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. Finally, B. Riley set a $10.00 target price on shares of Amyris and gave the company a “buy” rating in a research note on Wednesday, October 3rd.
In other Amyris news, CFO Kathleen Valiasek bought 23,000 shares of the firm’s stock in a transaction on Tuesday, November 27th. The stock was acquired at an average price of $4.37 per share, with a total value of $100,510.00. Following the completion of the purchase, the chief financial officer now owns 251,630 shares of the company’s stock, valued at $1,099,623.10. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eduardo Alvarez bought 11,877 shares of the firm’s stock in a transaction on Wednesday, September 5th. The shares were acquired at an average cost of $8.45 per share, with a total value of $100,360.65. Following the purchase, the chief operating officer now directly owns 331,877 shares of the company’s stock, valued at approximately $2,804,360.65. The disclosure for this purchase can be found here. 21.80% of the stock is currently owned by company insiders.
AMRS stock opened at $4.94 on Wednesday. Amyris has a 1 year low of $3.11 and a 1 year high of $9.28. The stock has a market capitalization of $345.89 million, a P/E ratio of -1.62 and a beta of 0.27.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. During the same period in the prior year, the firm posted ($0.81) earnings per share. Amyris’s quarterly revenue was down 38.4% compared to the same quarter last year. On average, analysts anticipate that Amyris will post -1.34 EPS for the current year.
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.